Classical Hodgkin Lymphoma, Lymphocyte-Depleted Classical Hodgkin Lymphoma, Lymphocyte-Rich Classical Hodgkin Lymphoma, Mixed Cellularity Classical Hodgkin Lymphoma, Nodular Sclerosis Classical Hodgkin Lymphoma
Conditions
Brief summary
The purpose of this research study is to evaluate a new drug pembrolizumab in combination with chemotherapy, for the treatment of newly diagnosed Hodgkin lymphoma. The chemotherapy regimen is called AVD and includes three drugs: adriamycin, vinblastin, dacarbazine. Pembrolizumab is currently FDA approved for the treatment of some patients with melanoma, lung cancer and head and neck cancer, but has not yet been approved for the treatment of Hodgkins Lymphoma. The AVD regimen of chemotherapy is currently FDA approved for the treatment of newly diagnosed Hodgkin lymphoma, but has not yet been investigated in combination with pembrolizumab for this disease. For patients who have a new diagnosis of Hodgkins Lymphoma, multi-agent chemotherapy is recommended. Also, for patients who do not have a complete response to chemotherapy (meaning there is still evidence of disease on PET scans performed at the end of treatment), radiation is sometimes recommended. Furthermore, the rare patient who relapses after chemotherapy requires treatment with high dose chemotherapy and a transplant.
Detailed description
PRIMARY OBJECTIVES: I. Assess the percent of patients who achieve a complete response (CR) to single-agent pembrolizumab induction, among patients with classical Hodgkin lymphoma (cHL) using Lugano 2014 criteria., as measured at PET #2. SECONDARY OBJECTIVES: I. Assess the safety and tolerability of pembrolizumab in combination with chemotherapy in the frontline setting. II. Determine the three-year progression free survival (PFS) and overall survival (OS) for patients \< 60 with early non-bulky disease, and elderly patients (all stages) treated with pembrolizumab with doxorubicin hydrochloride (Adriamycin), (bleomycin), vinblastine sulfate, dacarbazine (A\[B\]VD) in the frontline treatment of patients with cHL. III. Determine the extent of fludeoxyglucose F-18 (FDG) uptake, using a semi-quantitative approach (e.g., Deauville score), after pembrolizumab induction, and after subsequent chemotherapy. TERTIARY OBJECTIVES: I. To characterize PD-1 pathway specific expression and correlate with response. II. To characterize serum biomarkers of immune and inflammatory response during treatment. III. To characterize levels of soluble PD-L1 related to treatment with pembrolizumab. IV. To characterize T-lymphocyte subset changes to treatment with pembrolizumab. V. To investigate the prevalence and clinical correlation of chromosome 9p24.1 alterations for this population. OUTLINE: INITIATION: Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients also undergo FDG-PET/computed tomography (CT) scans before the start of pembrolizumab and after 3 courses. AVD: Within 21 days after final dose of pembrolizumab, patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, and dacarbazine IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo a final FDG-PET/CT scan on day 117-120 or 26-29 of course 2. Patients with stage I/II disease with a CR continue treatment for up to 2 courses. Patients with stage III/IV disease with a CR or age \>= 60 with stage III/IV disease with any response continue treatment for up to 4 courses. CONSOLIDATION: Patients age \>= 60 with stage III/IV disease who received \< 6 courses of AVD or patients age \>= 60 with DV 4-5 on FDG-PECT/CT scan receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for 2 years.
Interventions
BIOLOGICALPembrolizumab
Given IV
PROCEDUREComputed Tomography
Undergo FDG-PET/CT
DRUGDacarbazine
Given IV
DRUGDoxorubicin Hydrochloride
Given IV
RADIATIONFludeoxyglucose F-18
Undergo FDG-PET/CT
OTHERLaboratory Biomarker Analysis
Correlative studies
PROCEDUREPositron Emission Tomography
Undergo FDG-PET/CT
DRUGVinblastine Sulfate
Given IV
Sponsors
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Northwestern University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must have a histologically confirmed diagnosis of classical Hodgkin lymphoma including nodular sclerosis, mixed cellularity, lymphocytic-rich, and lymphocyte depleted subtypes by the 4th edition of the World Health Organization (WHO) Classification of Tumors of Hematopoietic and Lymphoid Tissues published in 2008 (nodular lymphocyte-predominant Hodgkin lymphoma \[NLPHL\] excluded) * Patients must have measurable disease by the Lugano criteria * Patients must have previously untreated disease (except for one week or less of corticosteroids) * Patients must exhibit a/an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 * Patients may have any stage and any International Prognostic Score (IPS) * Patients must have adequate organ and bone marrow function within 14 days prior to registration, as defined below: * Leukocytes \>= 3,000/mcL * Absolute neutrophil count \>= 1,500/mcL * Platelets \>= 100,000/mcl * Total bilirubin within normal institutional limits * Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT)(serum glutamate pyruvate transaminase \[SGPT\]) =\< 2.5 X institutional upper limit of normal (ULN) * Creatinine within normal institutional limits * Platelet transfusions are acceptable prior to treatment to achieve the above numbers, however growth factors are not allowed within 14 days of registration * Females of child-bearing potential (FOCBP) and males must agree to avoid becoming pregnant, or impregnating a partner, respectively, by complying with any of the approved contraception techniques prior to registration, for the duration of study participation, and for 120 days following completion of therapy; abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject; should a female patient become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately NOTE: A FOCBP is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria: * Has not undergone a hysterectomy or bilateral oophorectomy * Has had menses at any time in the preceding 12 consecutive months (and therefore has not been naturally postmenopausal for \> 12 months) * FOCBP must have a negative pregnancy test within 7 days prior to registration on study; NOTE: a negative pregnancy test is also required within 3 days prior to first dose of pembrolizumab and therefore may need to be repeated if screening test is more than 3 days prior to first dose * Patients must have the ability to understand and the willingness to sign a written informed consent prior to registration on study
Exclusion criteria
* Patients are not eligible who have had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to registration or who have not recovered (i.e., =\< grade 1 or at baseline) from adverse events due to a previously administered agent * NOTE: Subjects with =\< grade 2 neuropathy are an exception to this criterion and may qualify for the study * NOTE: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy * Patients who have a diagnosis of immunodeficiency or are receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to registration are not eligible * Patients who have a known history of active TB (bacillus tuberculosis) are not eligible * Patients must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab * Patients who have an uncontrolled intercurrent illness including, but not limited to any of the following, are not eligible: * Symptomatic congestive heart failure * Unstable angina pectoris * Cardiac arrhythmia * Patients who have a known additional malignancy that is progressing or requires active treatment are not eligible * NOTE: Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer * Patients who have known active central nervous system (CNS) metastases and/or carcinomatous meningitis are not eligible * NOTE: Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to registration; this exception does not include carcinomatous meningitis which is excluded regardless of clinical stability * Patients who have active autoimmune disease that has required systemic treatment in the past 2 years are not eligible (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs) * NOTE: Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment * Patients who have known history of, or any evidence of active, non-infectious pneumonitis are not eligible * Patients who have an active infection requiring systemic therapy are not eligible, except for uncomplicated urinary tract infections * Patients are not eligible who have a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject?s participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator * Patients who have known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial are not eligible * Patients may not be pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, from registration through 120 days after the last dose of trial treatment * Patients who have received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent are not eligible * Patients who have a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies) are not eligible * Patients who have active hepatitis B (e.g., hepatitis B virus surface antigen \[HBsAg\] reactive) or hepatitis C (e.g., hepatitis c virus \[HCV\] ribonucleic acid \[RNA\] \[qualitative\] is detected) are not eligible * Patients who received a live vaccine within 30 days of planned start of study therapy are not eligible; examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster, yellow fever, rabies, bacillus Calmette-Guerin (BCG), and typhoid vaccine * NOTE: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist) are live attenuated vaccines, and are not allowed
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Complete Response (CR) With Pembrolizumab Treatment Alone | After 3 cycles of pembrolizumab (1 cycle = 21 days) | To assess the primary objective of response rate following PET #2 performed after 3 doses of pembrolizumab. PET response will be assessed using the Lugano Criteria (2014) which recommends the 5 point Deauville score for assessing response. The Deauville five-point scale is an internationally-recommended scale for routine clinical reporting and clinical trials using FDG PET-CT in the initial staging and assessment of treatment response in Hodgkin lymphoma (HL). Patients with a Deauville score of 1-3 will be considered a complete response. Deauville criteria is defined as follows: 1. No residual uptake 2. Slight uptake, but below blood pool (mediastinum) 3. Uptake above mediastinum, but below or equal to uptake in the liver 4. Uptake slightly to moderately higher than liver 5. Markedly increased uptake or any new lesions Patients will be evaluable for response assessment if they have received at least one dose of pembrolizumab. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| OS for Elderly Patients | Up to 2 years | OS for elderly patients will be evaluated. |
| FDG Uptake | Up to 4 weeks after last dose of chemotherapy | Evaluate the extent of FDG uptake by assessing PET scans to determine a Deauville score. |
| Overall Survival (OS) for Patients <60 | Up to 2 years | OS for patients \<60 will be evaluated. |
| Progression Free Survival (PFS) for Patients <60 | Up to 2 years | PFS for patients \<60 will be measured. |
| PFS for Elderly Patients | Up to 2 years | PFS for elderly patients will be measured. |
| Incidence of Adverse Events | Up to 2 years | To assess safety and tolerability, all adverse events will be summarized in terms of type, grade, timing and attribution to treatment and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 (NCI-CTCAE version 4.03). |
Countries
United States
Participant flow
Recruitment details
The study opened to accrual on September 6th, 2017 with an accrual goal of 30 patients. The first patient was enrolled onto the study and started treatment on November 9th, 2017. The study closed permanently to further enrollment of participants on March,12th 2019 as the accrual goal was met.
Participants by arm
| Arm | Count |
|---|---|
| Treatment: Pembrolizumab and AVD Chemotherapy Guided by PET-CT All patients get 3 cycles (21-days each) of pembrolizumab (PEM) induction, then a PET-CT (PET#2). PET#2 required for primary endpoint analysis. Patients evaluable for response assessment if they had at least one dose of PEM.
After, all patients get 2 cycles (28-days each) of AVD (doxorubicin, vinblastine, dacarbazine), followed by an interim PET-CT (PET#3) for response analysis.
Depending on age, stage, and PET#3 results per Deauville (DV) Score, patients get additional 2-4 cycles of AVD, or AVD and escBEACOPP (escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) + radiotherapy (RT). Then, patients will have a PET-CT (PET#4) or a CT (CT if Stage I/II disease and negative for PET#3).
Patients under 60 go to survival follow-up. Patients over 60 go to survival follow-up or 1-2 years of PEM consolidation based on bulky vs non bulky disease, results of the PET#3, and the number of AVD cycles received.
See schema for details. | 30 |
| Total | 30 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| 2-4 Cycles of AVD +/- Chemo & RT, PET#4 | Transferred to another state | 1 |
| PEM Consolidation (1-2 Years) | Per Protocol not eligible | 29 |
| Survival Follow-up | Patients still in follow-up. | 30 |
Baseline characteristics
| Characteristic | Treatment: Pembrolizumab and AVD Chemotherapy Guided by PET-CT |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 4 Participants |
| Age, Categorical Between 18 and 65 years | 26 Participants |
| Bulky vs Non-Bulky Disease No | 16 Participants |
| Bulky vs Non-Bulky Disease Yes | 14 Participants |
| Disease Stage IIa | 6 Participants |
| Disease Stage IIb | 6 Participants |
| Disease Stage IIIa | 4 Participants |
| Disease Stage IIIb | 1 Participants |
| Disease Stage IVa | 6 Participants |
| Disease Stage IVb | 7 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 2 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 28 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 2 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants |
| Race (NIH/OMB) More than one race | 2 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 25 Participants |
| Region of Enrollment United States | 30 participants |
| Sex: Female, Male Female | 19 Participants |
| Sex: Female, Male Male | 11 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 30 |
| other Total, other adverse events | 30 / 30 |
| serious Total, serious adverse events | 6 / 30 |
Outcome results
Primary
Complete Response (CR) With Pembrolizumab Treatment Alone
To assess the primary objective of response rate following PET #2 performed after 3 doses of pembrolizumab. PET response will be assessed using the Lugano Criteria (2014) which recommends the 5 point Deauville score for assessing response. The Deauville five-point scale is an internationally-recommended scale for routine clinical reporting and clinical trials using FDG PET-CT in the initial staging and assessment of treatment response in Hodgkin lymphoma (HL). Patients with a Deauville score of 1-3 will be considered a complete response. Deauville criteria is defined as follows: 1. No residual uptake 2. Slight uptake, but below blood pool (mediastinum) 3. Uptake above mediastinum, but below or equal to uptake in the liver 4. Uptake slightly to moderately higher than liver 5. Markedly increased uptake or any new lesions Patients will be evaluable for response assessment if they have received at least one dose of pembrolizumab.
Time frame: After 3 cycles of pembrolizumab (1 cycle = 21 days)
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Treatment: Pembrolizumab and AVD Chemotherapy Guided by PET-CT | Complete Response (CR) With Pembrolizumab Treatment Alone | 37 percentage of participants |
Secondary
FDG Uptake
Evaluate the extent of FDG uptake by assessing PET scans to determine a Deauville score.
Time frame: Up to 4 weeks after last dose of chemotherapy
Secondary
Incidence of Adverse Events
To assess safety and tolerability, all adverse events will be summarized in terms of type, grade, timing and attribution to treatment and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 (NCI-CTCAE version 4.03).
Time frame: Up to 2 years
Secondary
OS for Elderly Patients
OS for elderly patients will be evaluated.
Time frame: Up to 2 years
Secondary
Overall Survival (OS) for Patients <60
OS for patients \<60 will be evaluated.
Time frame: Up to 2 years
Secondary
PFS for Elderly Patients
PFS for elderly patients will be measured.
Time frame: Up to 2 years
Secondary
Progression Free Survival (PFS) for Patients <60
PFS for patients \<60 will be measured.
Time frame: Up to 2 years
Post Hoc
Overall Survival at Treatment Completion
Overall survival will be defined as the number of patients that are alive at the time of treatment completion (3 cycles of pembrolizumab and 2-6 cycles of AVD)
Time frame: At completion of treatment with 3 cycles of pembrolizumab (21 day cycles) and up to 6 cycles of AVD (28 days cycles)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Treatment: Pembrolizumab and AVD Chemotherapy Guided by PET-CT | Overall Survival at Treatment Completion | 30 Participants |
Post Hoc
Progression Free Survival (PFS) at Treatment Completion
PFS is defined as the number of patients that are progression/relapse free at the time of treatment completion (3 cycles of pembrolizumab and up to 6 cycles of AVD). Progressive or relapse disease is defined as of the following: Appearance of any new lesion more than 1.5 cm in any axis during treatment, even if other lesions are decreasing in size. At least a 50% increased from nadir in the sum of the product of the diameter (SPD) of any previously involved nodes, or in a single involved node, or the size of other lesions (e.g., splenic or hepatic nodules). To be considered progressive disease, a lymph node with a diameter of the short axis of less than 1.0 cm must increase by at least 50% and to a size of more than 1.5 x 1.5 cm or more than 1.5 cm in the long axis. At least a 50% increase in the longest diameter of any single previously identified node more than 1.0 cm in its short axis. Lymphoma confirmed by repeat biopsy.
Time frame: At completion of treatment with 3 cycles of pembrolizumab (21 day cycles) and up to 6 cycles of AVD (28 days cycles)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Treatment: Pembrolizumab and AVD Chemotherapy Guided by PET-CT | Progression Free Survival (PFS) at Treatment Completion | 30 Participants |